Expectant management: An option for localized prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 8, Issue 4, 2005, Pages 311-315

  Khan, M A ^a   Partin, A W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Expectant management; Prostate adenocarcinoma

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; DISEASE COURSE; EARLY DIAGNOSIS; ERECTILE DYSFUNCTION; HUMAN; LIFE EXPECTANCY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; RISK FACTOR; URINARY TRACT OBSTRUCTION; URINE INCONTINENCE;

HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RISK FACTORS; SURVIVAL RATE;

EID: 30544437378     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500824     Document Type: Review

References (39)

1. Jemal A et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
2. Landis SH et al. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8-11.
3. Kelloff GJ et al. Chemoprevention strategies in the prostate: An overview. Rev Urol 2002; 4: 69-77.
4. Ries LAG et al (eds). SEER Cancer Statistics Review, 1973-1997. National Cancer Institute, Bethesda, MD, 2000.
5. Greenlee RT et al. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15-36.
6. Walsh PC, Donker PJ. Impotence following radical prostatectomy: Insight into etiology and prevention. J Urol 1982; 128: 492-497.
7. Wingo PA et al. Patterns of inpatients surgeries for the top four cancers in the United States, National Hospital Discharge Survey, 1988-95. Cancer Causes Control 2000; 11: 497-512.
8. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971; 284: 878-881.
9. Leung GM et al. Trends in breast cancer incidence in Hong Kong between 1973 and 1999: An age-period-cohort analysis. Br J Cancer 2002; 87: 982-988.
10. Feuer EJ, Merrill RM, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer - part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 1999; 91: 1025-1032.
11. Potosky AL, Feuer EJ, Levin DL. Impact of screening on incidence and mortality of prostate cancer in the United States. Epidemiol Rev 2001; 23: 181-186.
12. Perron L et al. PSA screening and prostate cancer mortality. Can Med Assoc J 2002; 166: 586-591.
13. Oliver SE, Gunnell D, Donovan JL. Comparison of trends in prostate-cancer mortality in England and Wales and the US. Lancet 2000; 355: 1788-1789.
14. Merrill RM. Changes in the use of radical prostatectomy for treating prostate cancer in the USA. Lancet 1996; 348: 963-964.
15. Tarone RE, Chu KC, Brawley OW. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 2000; 11: 167-170.
16. Holmberg L et al. A randomised trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347: 781-789.
17. Bill-Axelson A et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: 1977-1984.
18. Wilt TJ, Brawer MK. The prostate cancer intervention versus observation trial: A randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J Urol 1994; 152: 1914-1919.
19. Wilt TJ, Brawer MK. The prostate cancer intervention versus observation trial (PIVOT). Oncology 1997; 11: 1133-1139.
20. Etzioni R et al. Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002; 94: 981-990.
21. Epstein JI et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-374.
22. Humphrey PA et al. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol 1996; 155: 816-820.
23. Johansson J-E et al. Natural History of localised prostatic cancer. A population-based study in 223 untreated patients. Lancet 1989; 1: 799-803.
24. Johansson J-E et al. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1992; 267: 2191-2196.
25. Jones GW. Prospective, conservative management of localized prostate cancer. Cancer 1992; 70: 307-310.
26. Warner J, Whitmore Jr WJ. Expectant management of clinically localized prostate cancer. J Urol 1994; 152: 1761-1765.
27. Albertsen PC et al. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274: 626-631.
28. Albertsen PC et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975-980.
29. Johansson J-E et al. Fifteen year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997; 277: 467-471.
30. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293: 2095-2101.
31. Johansson JE et al. Natural history of early localized prostate cancer. JAMA 2004; 291: 2713-2719.
32. Carter HB et al. Prospective evaluation of men with stage T1c adenocarcinoma of the prostate. J Urol 1997; 157: 2206-2209.
33. Epstein JI, Walsh PC, Carter HB. Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol 2001; 166: 1688-1691.
34. Carter HB et al. Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology 1997; 49: 379-384.
35. Choo R et al. Feasibility study: Watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002; 167: 1664-1669.
36. Klotz L. Active surveillance with selective delayed intervention: Using natural history to guide treatment in good risk prostate cancer. J Urol 2004; 172 (5 Part 2): S48-S50.
37. Carter HB et al. Expectant management of nonpalpable prostate cancer with curative intent: Preliminary results. J Urol 2002; 167: 1231-1234.
38. Steineck G et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002; 347: 790-796.
39. Walsh PC et al. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology 2000; 55: 58-61.